What is the market's earnings forecast for Precipio next quarter?

What is Precipio's latest dividend and current dividend yield?

What were the key takeaways from Precipio’s earnings call?

What is the revenue and EPS growth rate for Precipio year over year?

What factors drove the changes in Precipio's revenue and profit?

What were the key takeaways from Precipio's earnings call?

Did Precipio beat or miss consensus estimates last quarter?

What is Precipio's gross profit margin?

- **Breakthrough Profitability**: Achieved $0.5 million EBITDA and $0.285 million cash from operations, ending reliance on external capital.
- **Revenue Surge**: 30% YoY growth to $6.8 million, with Pathology Services up 20% QoQ and Products Division up 16% QoQ.
- **Margin Expansion**: Pathology Services gross margin at 46%, total company margin at 44%, targeting >50% by mid-2026.
- **Strategic Shift**: Transitioning from cost-cutting to growth investments, including $120,000 lab expansion and technical support roles.
- **Shareholder Value**: Share price tripled year-to-date, with plans to leverage market cap growth for strategic opportunities.

**【CEO Summary Section】**
- **Financial Milestones**: Achieved first-time positive adjusted EBITDA of $469,000 and $285,000 in cash from operations, marking a $433,000 positive cash swing from Q2. Share price has tripled since the start of 2025.
- **Revenue Growth**: Total Q3 revenue reached $6.8 million (30% YoY, 20% QoQ), driven by:
  - **Pathology Services**: $6 million (20% QoQ growth, 46% gross margin up from 43%)
  - **Products Division**: $720,000 (16% QoQ growth, 30% YoY expansion)
- **Gross Margin Expansion**: Overall gross margin improved to 44%, with Pathology Services leading at 46%. Expecting >50% gross margin by mid-2026.
- **Strategic Investments**: 
  - $120,000 annual lab space expansion to separate clinical and product operations
  - Technical support specialist to accelerate customer onboarding, generating $50,000 incremental QoQ revenue
- **Operational Efficiency**: Absorbed 20% revenue growth in Pathology Services without significant fixed cost increases, maintaining margin expansion.
- **Future Priorities**: 
  - Double-digit growth in both divisions
  - Expand margins through scale
  - Invest cash in strategic partnerships and product innovation
  - Enhance investor engagement to drive share price appreciation

Precipio, Inc.(PRPO)-20251118-2025 Q3 Earnings call transcript

Patient Service

Provision for Bad Debts

United States

Italy

All Other Countries

PRPO

PRPO fundamentals

You can ask Aime